에 대한 최신 뉴스 Genmab (NASDAQ:GMAB) 주식

Genmab

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.

Coinbase Photo by Useacoin on Shutterstock

Equities

Large Cap

News

Movers

Trading Ideas

AAPL

ADBE

COIN

EXPE

GMAB

HOOD

IBKR

SAIL

이들 대형 주식은 지난주에 최악의 성과를 보였다. 이 주식이 당신의 포트폴리오에 있나요? 1. 테라다인(NASDAQ:TER)의 주가가 20.08% 하락했다. 이 회사는 포토닉 IC 테스트 회사인 퀀티파이 포토닉스(Quantifi Photonics)를 비공개 금액에 인수하기로 합의했다. 애널리스트들은 이 회사의 가격 전망을 하향 조정했다.

코인베이스, 애플, 로빈후드 등 지난주 급락한 대형주 12종목 (3월 10일-3월 14일)

Genmab AS

Evercore ISI Group analyst Daniel Markowitz initiates coverage on Bio-Techne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TECH#NASDAQ">TECH</a>) with a Outperform rating and announces Price Target of $75.

Price Target

Initiation

Analyst Ratings

TECH

Evercore ISI Group Initiates Coverage On Bio-Techne with Outperform Rating, Announces Price Target of $75

Elbit Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESLT#NASDAQ">ESLT</a>) reported quarterly earnings of $2.66 per share which beat the analyst consensus estimate of $1.95 by 36.41 percent. This is a 70.51 percent increase over earnings of $1.56 per share from the same period last year. The company reported quarterly sales of $1.93 billion which beat the analyst consensus estimate of $1.78 billion by 8.44 percent. This is a 18.78 percent increase over sales of $1.63 billion the same period last year.

Earnings

Earnings Beats

ESLT

Elbit Systems Q4 2024 Adj EPS $2.66 Beats $1.95 Estimate, Sales $1.93B Beat $1.78B Estimate

President Donald Trump has publicly praised Amazon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) founder&nbsp;and owner of The Washington&nbsp;Post, Jeff Bezos, for the significant changes he has implemented at the newspaper.
What Happened: President Trump,&nbsp;during an interview with television&nbsp;journalist Sharyl Attkisson, expressed his appreciation for Bezos&#8217; efforts to improve The Washington Post. &#8220;I&nbsp;think a guy like Bezos&nbsp;is — I've gotten to&nbsp;know him, and I think&nbsp;he's trying to do a&nbsp;real job. Jeff Bezos is&nbsp;trying to do a real&nbsp;job with The Washington Post,&#8221; Trump said.
Trump acknowledged a shift in Bezos&#8217; management of the Post during his first term, a change he claims was not previously evident. His comments refer to a series of high-profile decisions Bezos has made at the newspaper, including discontinuation of editorial support for a presidential candidate last fall, implementing a new directive for op-eds, and restructuring the Post&#8217;s newsroom. These changes have sparked significant backlash, leading to canceled subscriptions, staff departures, and accusations that Bezos is seeking to gain favor with Trump to further his business interests. Bezos has dismissed these claims, asserting that the changes at the Post are essential for regaining reader trust. SEE ALSO: <a href="https://www.benzinga.com/25/03/44370387/fed-put-on-standby-while-trump-put-may-be-kaput-analysts-expect-jerome-powell-to-pivot-to-a-measured-stance-amid-economic-uncertainty">Fed Put On Standby, While Trump Put May Be Kaput? Analysts Expect Jerome Powell To Pivot To A Measured Stance Amid Economic Uncertainty </a> Why It Matters: Bezos&#8217; overhaul of The Washington Post has been a topic of controversy. In February, the <a href="https://www.benzinga.com/25/02/43760885/jeff-bezos-owned-washington-post-turns-down-ad-campaign-that-asked-whos-running-this-country-donald-trump-or-elon-musk">newspaper rejected a provocative</a> "Fire Elon Musk" ad campaign by advocacy group Common Cause. This decision was part of a larger shift in the newspaper&#8217;s editorial policy. Also in February, Bezos, who attended Trump&#8217;s inauguration, announced a significant shift in the newspaper's opinion section, <a href="https://www.benzinga.com/general/social-media/25/02/43997193/jeff-bezos-washington-post-overhaul-draws-oligarch-remark-from-bernie-sanders-elon-musk-calls-amazon-founder-a-bravo">prioritizing viewpoints</a> supporting free markets and personal liberties. This move has drawn both praise and criticism, with some accusing Bezos of using the newspaper to advance his personal and business interests. Former Labor Secretary Robert Reich condemned this move as he said, &#8220;..it's not a win for free speech. It's a win for oligarchy." On the other hand, Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) CEO Elon Musk, responded to this move on X with "Bravo, Jeff Bezos!"
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="President Trump says immigration, the economy and the war in Ukraine are all on his short list." width="500" height="281" src="https://www.youtube.com/embed/Y16M67qNot8?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
READ MORE:
<ul>
<li><a href="https://www.benzinga.com/25/03/44370877/trump-ally-larry-ellisons-oracle-pledges-5-billion-to-boost-uks-ai-driven-cloud-infrastructure">Trump Ally Larry Ellison&#8217;s Oracle Pledges $5 Billion To Boost UK&#8217;s AI-Driven Cloud Infrastructure</a></li>
</ul>
Image via Shutterstock Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Government

Politics

AMZN

TSLA

Trump Praises Jeff Bezos' Recent Moves With Washington Post: 'He's Trying To Do A Real Job'

Evercore ISI Group analyst Daniel Markowitz initiates coverage on Repligen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGEN#NASDAQ">RGEN</a>) with a In-Line rating and announces Price Target of $155.

RGEN

Evercore ISI Group Initiates Coverage On Repligen with In-Line Rating, Announces Price Target of $155

Tencent Music Entertainment Group Declared A Cash Dividend Of $0.09 Per Ordinary Share, Or $0.18 Per ADS, To Holders Of Record As Of Close Of Business On April 3

Tencent Music Entertainment Group Says It Has Recently Authorized A New Share Repurchase Program Under Which It May Repurchase Up To $1B Of Its Class A Ordinary Shares During 24-month Period Commencing From March 2025

As the Magnificent 7 companies have estimated a total capital expenditure of over $330 billion on the artificial intelligence infrastructure in 2025, there is a possibility that China&#8217;s AI breakthrough, despite chip shortage, could affect their targets, affecting profitability.
What Happened: The Magnificent 7 companies are widely expected to spend more than $330 billion on capex in 2025. While the chipmaker Nvidia Corp. hasn&#8217;t explicitly mentioned a target during its earnings call, the iPhone maker Apple Inc. broadly expects to spend <a href="https://www.benzinga.com/government/regulations/25/02/43912631/apple-forced-to-kiss-the-ring-expert-questions-whether-trump-pushed-the-iphone-maker-for-500-billion-investment">$500 billion</a> over the next four years.
The remaining companies, however, have provided a specific target for 2025.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Stocks</td>
<td>CAPEX Target For 2025</td>
<td>YTD Performance</td>
</tr>
<tr>
<td>Nvidia Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)</td>
<td>&#8211;</td>
<td>-13.58%</td>
</tr>
<tr>
<td>Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>)</td>
<td>&#8211;</td>
<td>-12.24%</td>
</tr>
<tr>
<td>Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>)</td>
<td>$80 Billion</td>
<td>-7.14%</td>
</tr>
<tr>
<td>Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>)</td>
<td>$100 Billion</td>
<td>-11.12%</td>
</tr>
<tr>
<td>Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>)</td>
<td>$75 Billion</td>
<td>-13.27%</td>
</tr>
<tr>
<td>Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>)</td>
<td>$65 Billion</td>
<td>0.94%</td>
</tr>
<tr>
<td>Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)</td>
<td>$11 Billion</td>
<td>-37.25%</td>
</tr>
</tbody>
</table>
</figure>
According to Edward Yardeni, the President of Yardeni Research, the &#8220;AI bubble&#8221; could be &#8220;bursting&#8221; as China continues to scale its AI-linked technology with inexpensive chips.
He said, &#8220;The fear now is that open-source large language models (LLMs) like DeepSeek and Manus, developed in China, require much less powerful semiconductors to operate.&#8221;
&#8220;If so, then AI capital spending will tumble along with the profit margins on AI systems,&#8221; adds Yardeni.
See Also: <a href="https://www.benzinga.com/25/03/44370387/fed-put-on-standby-while-trump-put-may-be-kaput-analysts-expect-jerome-powell-to-pivot-to-a-measured-stance-amid-">Fed Put On Standby, While Trump Put May Be Kaput? Analysts Expect Jerome Powell To Pivot To A Measured Stance Amid Economic Uncertainty</a>
Why It Matters: All Magnificent 7 companies have underperformed in 2025, except Meta Platforms Inc. The exchange-traded fund that tracks these seven companies, Roundhill Magnificent Seven ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/MAGS#BATS">MAGS</a>), has declined by 12.87% on a year-to-date basis.
Since DeepSeek was introduced on Jan. 24, MAGS has been down by 16.21% according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
<figure class="wp-block-image size-large"><a href="https://pro.benzinga.com/dashboard"><img loading="lazy" decoding="async" width="1024" height="576" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/18035026/Roundhill-since-DeepSeek-1024x576.png" alt="" class="wp-image-828803" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/18035026/Roundhill-since-DeepSeek-1024x576.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/18035026/Roundhill-since-DeepSeek-300x169.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/18035026/Roundhill-since-DeepSeek-768x432.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/18035026/Roundhill-since-DeepSeek-1536x864.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/18035026/Roundhill-since-DeepSeek.png 1920w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
The underperformance of Magnificent 7 companies can be attributed to "interest rate sensitivity," "unraveling trade tensions," and the high concentration of these stocks in the S&amp;P 500's market capitalization amid the market correction, according to John Murillo, the chief dealing officer at B2BROKER.
Price Action: The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, rose on Monday. The SPY advanced 0.77% to $567.15, and the QQQ also jumped 0.65% to $482.77, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44354638/mark-cuban-advises-genz-to-spend-every-waking-minute-learning-about-ai-amid-disruption-heres-a-list-of-ai-investment-opportunities-for-long-term" target="_blank" rel="noreferrer noopener">Mark Cuban Advises GenZ To ‘Spend Every Waking Minute Learning About AI:' Here's A List Of AI Investment Opportunities For Long Term</a></li>
</ul>
Photo courtesy: Shutterstock

Markets

Tech

GOOGL

MAGS

MSFT

NVDA

AI Bubble Bursting? Magnificent 7's Profit Margins Face Pressure As 'Capital Spending Can Tumble' In 2025

Tencent Music Enter Gr Q4 Adj EPADS $0.20, Sales $1.02B Beat $1.01B Estimate

Aurora Mobile's SendCloud And SaleSmartly Forge Strategic Alliance To Elevate Global Email Marketing Performance

Evercore ISI Group analyst Daniel Markowitz initiates coverage on West Pharmaceutical Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>) with a Outperform rating and announces Price Target of $275.

Evercore ISI Group Initiates Coverage On West Pharmaceutical Servs with Outperform Rating, Announces Price Target of $275

General

Marriott's Subsidiary Ritz-Carlton Hotel Debuts In Suzhou City Near Shanghai

<h3>Companies Reporting Before The Bell</h3>
• Bitcoin Depot (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTM#NASDAQ">BTM</a>) is likely to report quarterly loss at $0.01 per share on revenue of $131.50 million. 
• United Maritime (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/USEA#NASDAQ">USEA</a>) is expected to report quarterly loss at $0.41 per share on revenue of $9.50 million. 
• Flowco Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLOC#NYSE">FLOC</a>) is estimated to report quarterly earnings at $0.35 per share on revenue of $185.00 million. 
• Eton Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETON#NASDAQ">ETON</a>) is estimated to report quarterly loss at $0.02 per share on revenue of $10.68 million. 
• MiNK Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INKT#NASDAQ">INKT</a>) is expected to report earnings for its fourth quarter. 
• Citi Trends (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTRN#NASDAQ">CTRN</a>) is likely to report quarterly earnings at $0.18 per share on revenue of $211.54 million. 
• McEwen Mining (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MUX#NYSE">MUX</a>) is projected to report earnings for its fourth quarter. 
• ZKH Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZKH#NYSE">ZKH</a>) is estimated to report earnings for its fourth quarter. 
• HUYA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUYA#NYSE">HUYA</a>) is expected to report quarterly earnings at $0.04 per share on revenue of $215.25 million. 
• XPeng (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NYSE">XPEV</a>) is projected to report earnings for its fourth quarter. 
• UP Fintech Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIGR#NASDAQ">TIGR</a>) is expected to report earnings for its fourth quarter. 
• KE Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BEKE#NYSE">BEKE</a>) is expected to report quarterly earnings at $0.26 per share on revenue of $4.01 billion. 
• Tencent Music Enter Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TME#NYSE">TME</a>) is expected to report quarterly earnings at $0.19 per share on revenue of $1.01 billion. 
• Bakkt Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKKT#NYSE">BKKT</a>) is likely to report earnings for its fourth quarter. 
• OneConnect Financial Tech (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OCFT#NYSE">OCFT</a>) is likely to report earnings for its fourth quarter. 
• IHS Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IHS#NYSE">IHS</a>) is projected to report quarterly earnings at $0.08 per share on revenue of $413.76 million. 
• Acurx Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACXP#NASDAQ">ACXP</a>) is projected to report earnings for its fourth quarter. 
• Elbit Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESLT#NASDAQ">ESLT</a>) is estimated to report quarterly earnings at $1.95 per share on revenue of $1.78 billion. 
• SNDL (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDL#NASDAQ">SNDL</a>) is expected to report earnings for its fourth quarter. 
• NeoGenomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEO#NASDAQ">NEO</a>) is projected to report earnings for its fourth quarter. 
<h3>Companies Reporting After The Bell</h3>
• ZTO Express (Cayman) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTO#NYSE">ZTO</a>) is likely to report quarterly earnings at $0.46 per share on revenue of $1.66 billion. 
• Inovio Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>) is estimated to report quarterly loss at $0.93 per share on revenue of $30 thousand. 
• Trevi Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRVI#NASDAQ">TRVI</a>) is projected to report earnings for its fourth quarter. 
• LexinFintech Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LX#NASDAQ">LX</a>) is estimated to report earnings for its fourth quarter. 
• Better Home &amp; Finance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BETR#NASDAQ">BETR</a>) is likely to report earnings for its fourth quarter. 
• Surf Air Mobility (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SRFM#NYSE">SRFM</a>) is projected to report quarterly loss at $1.19 per share on revenue of $26.90 million. 
• Aterian (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATER#NASDAQ">ATER</a>) is estimated to report quarterly loss at $0.63 per share on revenue of $23.69 million. 
• Absci (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABSI#NASDAQ">ABSI</a>) is likely to report quarterly loss at $0.21 per share on revenue of $1.82 million. 
• OmniAb (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OABI#NASDAQ">OABI</a>) is likely to report quarterly loss at $0.10 per share on revenue of $10.13 million. 
• HealthEquity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) is estimated to report quarterly earnings at $0.72 per share on revenue of $305.07 million. 
• StoneCo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STNE#NASDAQ">STNE</a>) is projected to report quarterly earnings at $0.35 per share on revenue of $647.56 million. 
• Waldencast (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WALD#NASDAQ">WALD</a>) is likely to report quarterly loss at $0.25 per share on revenue of $272.22 million. 
• Orla Mining (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ORLA#AMEX">ORLA</a>) is likely to report earnings for its fourth quarter. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ABSI

ACXP

ATER

BEKE

BETR

Bakkt Holdings, Inc. Class A Common Stock

BKKT

CTRN

ETON

FLOC

HUYA

INKT

OABI

OCFT

ORLA

SNDL

SRFM

STNE

TIGR

TRVI

USEA

WALD

XPEV

Earnings Scheduled For March 18, 2025

Williams-Sonoma, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSM#NYSE">WSM</a>) will release its fourth-quarter financial results, before the <a href="https://www.benzinga.com/quote/WSM/earnings">opening bell, on Wednesday, March 19.</a>
Analysts expect the San Francisco, California-based company to report quarterly earnings at $2.93 per share, up from $2.72 per share in the year-ago period. Williams-Sonoma projects quarterly revenue of $2.35 billion, compared to $2.28 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On Nov. 20, 2024, Williams-Sonoma reported better-than-expected third-quarter financial results and approved a $1 billion stock repurchase authorization.
Williams-Sonoma shares rose 4.5% to close at $175.00 on Monday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/wsm/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li>Goldman Sachs analyst Kate McShane maintained a Neutral rating and increased the price target from $170 to $224 on Jan. 30, 2025. This analyst has an accuracy rate of 67%.</li>
<li>Morgan Stanley analyst Simeon Gutman maintained an Equal-Weight rating and raised the price target from $170 to $195 on Jan. 21, 2025. This analyst has an accuracy rate of 67%.</li>
<li>Wells Fargo analyst Zachary Fadem maintained an Equal-Weight rating and raised the price target from $165 to $185 on Jan. 6, 2025. This analyst has an accuracy rate of 84%.</li>
<li>Wedbush analyst Seth Basham maintained a Neutral rating and raised the price target from $135 to $175 on Nov. 21, 2024. This analyst has an accuracy rate of 68%.</li>
<li>TD Cowen analyst Max Rakhlenko maintained a Buy rating and boosted the price target from $165 to $195 on Nov. 21, 2024. This analyst has an accuracy rate of 64%.</li>
</ul>
Considering buying WSM stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="590" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/11123018/image-69-1024x590.png" alt="" class="wp-image-819195" style="width:609px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/11123018/image-69-1024x590.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/11123018/image-69-300x173.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/11123018/image-69-768x443.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/11123018/image-69.png 1102w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/03/44245496/top-3-health-care-stocks-that-may-keep-you-up-at-night-in-q1">Top 3 Health Care Stocks That May Keep You Up At Night In Q1</a></li>
</ul>

Pre-Market Outlook

Williams-Sonoma Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

HUYA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUYA#NYSE">HUYA</a>) reported quarterly sales of $204.93 million which missed the analyst consensus estimate of $215.25 million by 4.80 percent. This is a 4.89 percent decrease over sales of $215.47 million the same period last year.

Earnings Misses

HUYA Q4 Sales $204.93M Miss $215.25M Estimate

General Mills, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GIS#NYSE">GIS</a>) will release its third-quarter financial results, before the <a href="https://www.benzinga.com/quote/GIS/earnings">opening bell, on Wednesday, March 19.</a>
Analysts expect the company to report quarterly earnings at 96 cents per share, down from $1.17 per share in the year-ago period. General Mills projects quarterly revenue of $4.95 billion, compared to $5.1 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On Jan. 27, General Mills finalized the sale of its Canadian yogurt division to Sodiaal. The transaction includes the Canadian operations of well-known yogurt brands such as Yoplait and Liberté, as well as a production facility in Saint-Hyacinthe, Québec..
General Mills shares gained 2.3% to close at $60.94 on Monday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/gis/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li>JP Morgan analyst Ken Goldman maintained a Neutral rating and cut the price target from $62 to $60 on March 11, 2025. This analyst has an accuracy rate of 78%.</li>
<li>Jefferies analyst Rob Dickerson maintained a Hold rating and raised the price target from $58 to $62 on March 10, 2025. This analyst has an accuracy rate of 68%.</li>
<li>Piper Sandler analyst Michael Lavery maintained an Overweight rating and cut the price target from $84 to $71 on Feb. 25, 2025. This analyst has an accuracy rate of 66%.</li>
<li>Wells Fargo analyst Chris Carey maintained an Equal-Weight rating and cut the price target from $64 to $61 on Feb. 19, 2025. This analyst has an accuracy rate of 63%.</li>
<li>B of A Securities analyst Bryan Spillane maintained a Buy rating and slashed the price target from $78 to $70 on Feb. 19, 2025. This analyst has an accuracy rate of 62%.</li>
</ul>
Considering buying GIS stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="575" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/18042257/image-142-1024x575.png" alt="" class="wp-image-828877" style="width:619px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/18042257/image-142-1024x575.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/18042257/image-142-300x169.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/18042257/image-142-768x432.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/18042257/image-142.png 1107w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next:
<ul>
<li> <a href="https://www.benzinga.com/markets/25/03/44355158/jim-cramer-says-this-tech-stock-is-a-meme-stock-recommends-buying-accenture">Jim Cramer Calls This Stock A &#8216;Meme Stock,&#8217; Recommends Buying Accenture</a></li>
</ul>

Top Wall Street Forecasters Revamp General Mills Price Expectations Ahead Of Q3 Earnings

UP Fintech Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIGR#NASDAQ">TIGR</a>) reported quarterly earnings of $0.17 per share which beat the analyst consensus estimate of $0.11 by 56.36 percent. This is a 2357.14 percent increase over earnings of $0.01 per share from the same period last year. The company reported quarterly sales of $124.10 million which beat the analyst consensus estimate of $97.00 million by 27.94 percent. This is a 77.34 percent increase over sales of $69.98 million the same period last year.

UP Fintech Holding Q4 Adj $0.17 Beats $0.11 Estimate, Sales $124.10M Beat $97.00M Estimate

Sprinklr Launches Local Data Hosting Solution In Germany Through Collaboration With Google Cloud

NDAQ

Nasdaq And nuam Extend Partnership To Drive Capital Market Integration In Latin America

Nokia Launches Two New 25G PON Fiber Modems Designed To Deliver Mass-Market High-Speed Residential Connectivity

CLVT

Clarivate Joins With AI Company Iprova To Capture, Create And Refine Inventive Concepts With IP Management Software IPfolio

Press Releases

Genmab to Showcase Strength and Breadth of Comprehensive Epcoritamab-bysp Development Program at 2024 American Society of Hematology (ASH) Annual Meeting

Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)

Investigational Epcoritamab (DuoBody® CD3xCD20) Monotherapy Achieves High Overall and Complete Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) in Preliminary Analysis

Two Data Analyses from Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable, Complete Responses as Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2024

Genmab Publishes 2024 Annual Report

EPKINLY® (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare for Additional Indication as a Treatment for Relapsed or Refractory Follicular Lymphoma

Genmab Announces Johnson & Johnson Decision Regarding HexaBody®-CD38

Investigational Rinatabart Sesutecan (Rina-S®) Continues to Show Encouraging Antitumor Activity in Patients with Advanced Ovarian Cancer

AbbVie

Alnylam Pharmaceuticals, Inc. - Common Stock

Alnylam Pharmaceuticals

Amgen

argenx

Ascendis Pharma A/S - American Depositary Shares

Ascendis Pharma

Biogen

BioMarin Pharmaceutical Inc. - Common Stock

Biomarin Pharmaceutical

BioNTech

Exact Sciences Corporation - Common Stock

Exact Sciences

Exelixis

Gilead Sciences

Halozyme Therapeutics, Inc. - Common Stock

Halozyme Therapeutics

Incyte

Insmed

Moderna

Neurocrine Biosciences, Inc. - Common Stock

Neurocrine Biosciences

Natera

BeiGene, Ltd. - American Depositary Shares

BeiGene

Vaxcyte

Regeneron Pharmaceuticals, Inc. - Common Stock

Regeneron Pharmaceuticals

Roivant Sciences

Summit Therapeutics

Sarepta Therapeutics, Inc. - Common Stock

Sarepta Therapeutics

United Therapeutics Corporation - Common Stock

United Therapeutics

Vertex Pharmaceuticals Incorporated - Common Stock

Vertex Pharmaceuticals

Truist Securities

Leerink Partners

HC Wainwright & Co.

BMO Capital

Morgan Stanley

이들 대형 주식은 지난주에 최악의 성과를 보였다. 이 주식이 당신의 포트폴리오에 있나요?
1. 테라다인(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TER#NASDAQ">TER</a>)의 주가가 20.08% 하락했다. 이 회사는 포토닉 IC 테스트 회사인 퀀티파이 포토닉스(Quantifi Photonics)를 <a href="https://www.benzinga.com//node/44236516" target="_blank" rel="noreferrer noopener">비공개 금액에 인수하기로 합의</a>했다. 애널리스트들은 이 회사의 <a href="https://www.benzinga.com/quote/ter/analyst-ratings" target="_blank" rel="noreferrer noopener">가격 전망을 하향 조정</a>했다.
2. 트레이드 데스크(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTD#NASDAQ">TTD</a>)의 주가가 16.90% 급락했다. 이는 아마도 관세와 무역 정책으로 인한 경제적 우려 때문이다.
3. 코인베이스 글로벌(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>)의 주가가 15.79% 하락했다. 이는 <a href="https://www.benzinga.com//node/44287858" target="_blank" rel="noreferrer noopener">비트코인이 관세 불확실성으로 인해 하락</a>했기 때문이다.
4. 세일포인트(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIL#NASDAQ">SAIL</a>)의 주가가 15.19% 하락했다.
5. 젠맙(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GMAB#NASDAQ">GMAB</a>)의 주가가 15.04% 하락했다. 이는 존슨앤드존슨(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>)이 HexaBody-CD38에 대한 전 세계 개발, 제조 및 상용화 라이선스를 받을 옵션을 행사하지 않기로 결정한 후 발생한 일이다. 젠맙은 <a href="https://www.benzinga.com//node/44221409" target="_blank" rel="noreferrer noopener">추가 임상 개발을 진행하지 않기로</a> 했다.
6. 인터랙티브 브로커스 그룹(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBKR#NASDAQ">IBKR</a>)의 주가가 12.52% 하락했다. 이는 아마도 관세 불확실성으로 인한 전반적인 시장 우려 때문일 것이다.
7. 델타 항공(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAL#NYSE">DAL</a>)의 주가가 12.26% 급락했다. 회사가 첫 분기 <a href="https://www.benzinga.com//node/44244750" target="_blank" rel="noreferrer noopener">매출과 이익 가이던스를 하향 조정</a>했기 때문이다.
8. 어도비(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADBE#NASDAQ">ADBE</a>)의 주가가 12.16% 하락했다. 이는 회사가 2분기 및 2025 회계연도 조정 EPS 가이던스를 발표했으며, 그 중간값이 예상보다 낮았기 때문이다. 여러 애널리스트들도 <a href="https://www.benzinga.com//node/44302063" target="_blank" rel="noreferrer noopener">가격 전망을 수정</a>했다.
9. 익스피디아 그룹(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXPE#NASDAQ">EXPE</a>)의 주가가 12.05% 하락했다. 이는 여행 관련 주식들이 <a href="https://www.benzinga.com//node/44259915" target="_blank" rel="noreferrer noopener">전반적인 매도세</a>로 인해 하락한 후 발생한 일이다. <a href="https://www.benzinga.com//node/44259915" target="_blank" rel="noreferrer noopener">델타 항공이</a><a href="https://www.benzinga.com//node/44259915" target="_blank" rel="noreferrer noopener"> 가이던스 하향 조정</a>을 발표했다.
10. 로빈후드 마켓(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>)의 주가가 11.66% 하락했다. 회사는 <a href="https://www.benzinga.com//node/44252567" target="_blank" rel="noreferrer noopener">2월 운영 데이터를 발표</a>했다.
11. 유나이티드 항공 그룹(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UAL#NASDAQ">UAL</a>)의 주가가 11.11% 하락했다. 이는 BofA 증권과 바클레이즈가 주식에 대한 <a href="https://www.benzinga.com/quote/ual/analyst-ratings" target="_blank" rel="noreferrer noopener">각각의 가격 전망을 하향 조정</a>했기 때문다.
12. 애플(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>)의 주가가 10.70% 하락했다. 이는 지속적인 관세 불확실성으로 인한 전반적인 시장 약세 때문이다.
사진 제공: Useacoin, Shutterstock
다음 읽어보기:
<ul>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%EC%95%B1%EB%9F%AC%EB%B9%88-%EC%8A%88%ED%8D%BC-%EB%A7%88%EC%9D%B4%ED%81%AC%EB%A1%9C-%EC%BB%B4%ED%93%A8%ED%84%B0-%EC%9D%B8%ED%85%94-%EB%93%B1-%EC%A7%80%EB%82%9C%EC%A3%BC-%EA%B8%89%EB%93%B1%ED%95%9C/" target="_blank" rel="noopener">앱러빈, 슈퍼 마이크로 컴퓨터, 인텔 등 지난주 급등한 대형주 10종목 (3월 10일-3월 14일)</a></li>
</ul>
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

Genmab

뉴스

에 대한 최신 뉴스 Genmab (NASDAQ:GMAB) 주식

일요일, 3월 16, 2025

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌